title: Soluble IL-2 receptor: a biomarker for assessing myositis activity.
abstract: OBJECTIVE
  To evaluate the clinical significance of serum soluble IL-2R (sIL-2R) in inflammatory myopathies.
  
  
  METHODS
  Serum sIL-2R and CK levels were determined in 27 patients with IM during periods of disease exacerbation and inactive disease and were compared to 20 healthy controls and 23 controls with noninflammatory elevated CK. The performance of sIL-2R and CK tests for assessing disease activity was compared.
  
  
  RESULTS
  sIL-2R levels were increased in patients with IM. Significantly higher sIL-2R levels were detected in patients with disease exacerbation than in patients with inactive disease. In patients with IM, the sIL-2R levels correlated with the CK levels. Based on ROC analysis, diagnostic accuracy of sIL-2R and CK tests for disease activity was similar. However, when the CK threshold was defined by the upper limit of the normal, the specificity for the CK test dropped to 58%.
  
  
  CONCLUSIONS
  Serum sIL-2R level could be useful to distinguish disease exacerbation from damage in IM, especially in patients with persistent elevated CK levels when a clinical muscular worsening is noted. For discrimination of the disease activity, CK testing requires the use of a different threshold than the upper limit of the normal.
authors.affiliation: Department of Rheumatology, CHU Clermont-Ferrand, Hôpital Gabriel Montpied, 63003 Clermont-Ferrand, France.
authors.forename: Anne
authors.identifier: 0000-0002-5025-0214
authors.initials: A
authors.lastname: Tournadre
authors.affiliation: Department of Rheumatology, CHU Clermont-Ferrand, Hôpital Gabriel Montpied, 63003 Clermont-Ferrand, France.
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Dubost
authors.affiliation: Department of Rheumatology, CHU Clermont-Ferrand, Hôpital Gabriel Montpied, 63003 Clermont-Ferrand, France.
authors.forename: Martin
authors.initials: M
authors.lastname: Soubrier
authors.affiliation: Department of Internal Medicine, CHU Clermont-Ferrand, Hôpital Estaing, 63003 Clermont-Ferrand, France.
authors.forename: Marc
authors.initials: M
authors.lastname: Ruivard
authors.affiliation: Department of Dermatology, CHU Clermont-Ferrand, Hôpital Estaing, 63003 Clermont-Ferrand, France.
authors.forename: Pierre
authors.initials: P
authors.lastname: Souteyrand
authors.affiliation: Emergency Department, CHU Clermont-Ferrand, Hôpital Gabriel Montpied, 63003 Clermont-Ferrand, France.
authors.forename: Jeannot
authors.initials: J
authors.lastname: Schmidt
authors.affiliation: Department of Neurology, CHU Clermont-Ferrand, Hôpital Gabriel Montpied, 63003 Clermont-Ferrand, France.
authors.forename: Pierre
authors.initials: P
authors.lastname: Clavelou
authors.affiliation: Immunology Laboratory, Faculty of Pharmacy, 63003 Clermont-Ferrand, France.
authors.forename: Arlette
authors.initials: A
authors.lastname: Tridon
authors.affiliation: Department of Rheumatology, CHU Clermont-Ferrand, Hôpital Gabriel Montpied, 63003 Clermont-Ferrand, France.
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Ristori
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009220:Myositis / Q000097:blood* / Q000175:diagnosis; D012372:ROC Curve; D015375:Receptors, Interleukin-2 / Q000097:blood*; D055815:Young Adult
chemical_list: D015415:Biomarkers; D015375:Receptors, Interleukin-2